Abstract

HSR24-142: Real-World Clinical Benefit Among Patients (pts) With Lower-Risk Myelodysplastic Syndromes (LR-MDS) Treated With Luspatercept.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call